GASTRIC CANCER

This Phase 3 trial is testing whether a new targeted drug called sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly an immunotherapy (rilvegostomig), can help people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specifi…

This large Phase 3 trial is testing whether a newer targeted drug, trastuzumab deruxtecan (Enhertu), combined with chemotherapy and possibly the immunotherapy pembrolizumab (Keytruda), works better than the current standard treatment for advanced HER2-positive stomach or gastroes…

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This phase 2 trial tests whether adding an experimental biologic called TRK-950 to the standard combination of ramucirumab and paclitaxel helps people with advanced stomach or gastroesophageal junction cancer. Participants receive either the standard two-drug regimen or the stand…

This Phase 3 trial tests whether a combination of two immunotherapy drugs (botensilimab and balstilimab) can help people with advanced stomach cancer live longer compared to standard treatment. The study includes 132 adults whose tumors have a specific genetic marker (MSI-H/dMMR)…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrin…

This study tests a new drug called AZD4360 in adults with advanced solid tumours that have a specific marker (CLDN18.2). The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial aims to find the safest dose and see if it shrin…

This trial investigates whether using a device that sends mild electrical pulses to the thigh muscles (neuromuscular electrical stimulation, or NMES) can prevent muscle loss and weakness after abdominal surgery for colorectal or gastric cancer. Some participants will also receive…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with chemotherapy and immunotherapy, in people with advanced HER2-positive stomach or esophageal cancer. The goal is to see if these combinations are safe and can shrink tumors. About 450 adults with cancer t…

This early-phase study tests a new drug, ASP2998, that targets a protein called TROP2 found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. The main goals are to check safety and find the right dose. About 428 adults wi…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This study tests whether adding the supplement taurine to a standard treatment (immunotherapy drug serplulimab plus chemotherapy) can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 96 adults whose tumors have a specific marker…

This phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This study tests a new drug that delivers a tiny dose of radiation directly to cancer cells that have a specific marker called FAP. The trial involves 112 adults with advanced cancers of the pancreas, stomach, esophagus, colon, ovary, head/neck, sarcoma, or mesothelioma. First, a…

This early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study tests whether adding the drug cadonilimab to standard chemotherapy (FLOT) helps people with a certain type of stomach or gastroesophageal junction cancer that can be removed with surgery. About 37 adults will receive the combination before and after surgery. The goal i…

This Phase 3 trial tests a new drug called BL-M05D1 against standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). The study will include 438 adults who have already tried one prior treatment. The goal is …

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This study tests an experimental drug called SHR-A1904 in 83 people with advanced solid tumors, including stomach and pancreatic cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This phase 3 trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy (S-1 and oxaliplatin) works better than chemo alone for people with stomach or gastroesophageal junction cancer that can be surgically removed. About 874 participants will receive …

This phase 2 trial is testing whether a combination of immunotherapy drugs (sintilimab, IBI310, and lenvatinib) can help people with non-metastatic dMMR/MSI-H stomach or colon cancers avoid radical surgery. About 34 participants will receive up to 24 weeks of treatment, and those…

This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…

This Phase 2 trial is testing several new drug combinations in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The study aims to see if these combinations can shrink tumors and keep them from growing for at least 6…

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This study tests IKS014, a drug designed to seek out and destroy HER2-positive cancer cells, in people with advanced solid tumors like breast, stomach, and gastroesophageal cancers. The main goals are to find the safest dose and check for early signs of tumor shrinkage. About 165…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This early-phase trial is testing a new targeted drug called CA-4948 combined with standard chemotherapy and immunotherapy for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. The study will enroll 42 participants an…

This early-stage trial tests a treatment called Anti-CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. The study enrolls about 110 adults with advanced colorectal, gastric, or other solid tumors that …

This study tests a new drug called ZGGS34 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and second, testing how well the drug works alone or with chemotherapy in patients whose tumors have…

This study tests a combination of fruquintinib (a drug that blocks blood vessel growth to tumors) and chemotherapy (albumin-paclitaxel), with or without a PD-1 antibody, for people with advanced stomach or gastroesophageal junction cancer whose first PD-1 treatment stopped workin…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This Phase 1 trial is testing an oral drug called AUR107 in 50 adults with advanced solid tumors that have come back after prior treatment. The study aims to find a safe dose and understand how the drug moves through the body. It is the first time AUR107 is being tested in humans…

This study tests whether a short-term diet low in leucine (an amino acid) can make standard chemo-immunotherapy work better for stomach cancer patients. About 108 people will follow the diet for 3 days during each treatment cycle. Researchers will check if this approach improves …

This early-stage study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responde…

This study tests a two-step treatment for people with advanced liver cancer (hepatocellular carcinoma) or metastatic stomach cancer that has worsened despite prior immunotherapy. First, doctors deliver a drug called tirapazamine directly into the liver tumor through a procedure c…

This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…

This study compares two types of surgery for patients with early-stage stomach cancer near the esophagus. One method adds a procedure to widen the stomach outlet, which may help prevent severe acid reflux after surgery. The trial will track reflux, quality of life, and complicati…

This study tests whether using a reinforcement patch on surgical staplers can lower the risk of leaks and other complications after stomach cancer surgery. About 382 patients will be randomly assigned to receive either the reinforced stapler or a standard stapler during their ope…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This early-stage trial is testing a virus called IVX037, which is injected directly into tumours to kill cancer cells. It is being studied alone and combined with an immunotherapy drug (sintilimab) in people with advanced colorectal, gastric, or ovarian cancers that have stopped …

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This early-stage trial is testing a new type of immune cell therapy called armored dendritic cells in 8 people with solid cancers like pancreatic or colorectal cancer. Participants have already had surgery and at least 4 rounds of chemotherapy. The goal is to see if the treatment…

This study tests whether adding an immune-boosting drug (thymosin alpha 1) to standard chemo-immunotherapy can improve outcomes for people with stage III gastroesophageal junction cancer. About 48 participants will receive either the standard treatment or the standard plus thymos…

This study tests a combination of two drugs, carilizumab and albumin paclitaxel, as a second treatment for people with advanced stomach cancer. It includes 40 adults aged 18-75 who have already tried one prior treatment, with or without immunotherapy. The goal is to see if this c…

This phase 3 trial tests whether adding heated chemotherapy (HIPEC) directly into the abdomen after stomach cancer surgery can help patients live longer and prevent cancer from coming back in the belly. About 616 adults with advanced stomach cancer will be split into two groups: …

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…

This study tests a combination of two drugs, MCLA-129 and ensartinib, in people with advanced solid tumors that cannot be cured. The drugs work by blocking certain proteins that help cancer grow. The trial has two phases: first to find the safest dose, then to see if the combo sh…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This study tests whether adding an immune-boosting drug (thymalfasin) to standard chemotherapy and immunotherapy can help shrink stage III stomach or gastroesophageal junction cancer before surgery. About 30 adults aged 18-75 will receive the combination, then have their tumor ti…

This Phase 3 trial tests whether adding an experimental antibody (HLX22) to standard treatment (trastuzumab plus chemotherapy) works better for people with advanced HER2-positive stomach or gastroesophageal junction cancer. About 550 participants will be randomly assigned to rece…

This study tests an experimental drug called AZD5863 in adults with advanced stomach, gastro-esophageal junction, pancreatic, or esophageal cancers that have spread. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to attack them. The main go…

This study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…

This study tests whether a new type of radiation machine that uses MRI to guide treatment is safe and practical for people with gastric, breast, or other cancers. About 70 adults will receive radiation guided by real-time MRI, sometimes with chemotherapy. The goal is to see if th…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This study looks at different drug combinations for people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. Researchers will observe 250 participants receiving albumin-bound paclitaxel-based regimens, including immune check…

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to help the immune system attack cancer, followed by a…

This early-stage trial tests an experimental oral drug called CSCJC3456 in 102 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can shrink tumors. Participants take the table…

This phase 3 trial is testing whether a personalized program of supplements (vitamin D, mushroom extract, fish oil, probiotics, and whey protein) plus lifestyle coaching can improve recovery and quality of life for people undergoing surgery for lung, stomach, or esophageal cancer…

This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, rectal, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab…

This early-phase trial is testing a new drug called BDC-4182 in people with advanced gastric or gastroesophageal cancer that has spread or cannot be removed. The drug is designed to attach to a protein on cancer cells and stimulate the immune system to attack them. The study will…

This early-phase trial is testing an experimental drug called TH9619 in about 43 adults with advanced solid tumors, including colorectal, head and neck, lung, and gastric cancers. The main goal is to check the drug's safety and find the right dose. Participants must have already …

This early-stage trial is testing a new drug, BM230, in people with advanced solid tumors, especially those linked to HER2. The study has two parts: first, finding the safest dose, then expanding to see how well it works. About 123 participants will be enrolled worldwide.

This study is for people with stomach cancer that has spread to a few other places in the body. It tests whether adding surgery and other local treatments to a combination of immunotherapy and chemotherapy helps people live longer without the cancer getting worse. About 84 adults…

This study tests a combination of two drugs, savolitinib and durvalumab, in people with advanced stomach cancer that has a specific gene change called MET amplification. Participants must have already tried at least one chemotherapy that didn't work. The goal is to see if this co…

This study tests whether combining the targeted drug cabozantinib with immunotherapy drugs (durvalumab, with or without tremelimumab) is safe and effective for people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that c…

This study tests whether a combination of two drugs (camrelizumab and apatinib) can help people with advanced stomach or gastroesophageal junction cancer live longer compared to standard chemotherapy. The trial includes 550 adults whose cancer progressed after first-line platinum…

This early-stage study tests an experimental oral drug called DPTX3186 in 40 adults with advanced solid tumors (like colorectal, gastric, lung, or triple-negative breast cancer) that are linked to a specific cell signal called Wnt. These participants have no other approved treatm…

This Phase 2 study is testing several new drug combinations for people with stomach or gastroesophageal junction cancer who have not had prior treatment. The combinations include an immunotherapy drug (adebrelimab) plus targeted drugs (SHR-A1811, SHR-A1904, or SHR-8068) and chemo…

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This study tests whether taking glutamine by mouth can help gastric cancer patients regain muscle and improve nutrition after having their stomach removed. About 120 adults who had stomach cancer surgery will take glutamine supplements and be monitored for changes in muscle size,…

This early-stage study tests whether combining two drugs (sacituzumab govitecan and capecitabine) is safe for people with advanced gastrointestinal cancers that have stopped responding to standard treatments. About 20 adults with stomach, colorectal, or pancreatic cancer will tak…

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This study tests whether adding a probiotic called Saccharomyces boulardii to a standard antibiotic cocktail helps clear Helicobacter pylori infections that didn't respond to earlier treatments. About 1,248 adults who have failed prior H. pylori therapy will be randomly assigned …

This trial tests capmatinib, a drug already approved for certain lung cancers, in adults with rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if it can shrink tumors or stop them from growing for at least 24 weeks. The goal is …

This study compares standard chemotherapy alone versus chemotherapy plus a special procedure called PIPAC (pressurized intraperitoneal aerosol chemotherapy) for people with stomach cancer that has spread to the lining of the abdomen. About 106 adults aged 18-75 will take part. Th…

This study tests a combination of three drugs—lenvatinib, nivolumab, and chemotherapy—in people with advanced stomach cancer that has spread to the lining of the abdomen and caused fluid buildup (ascites). The goal is to see if this triple therapy can shrink tumors and help patie…

This clinical trial is testing a new biological therapy called GAIA-102, alone or combined with the immunotherapy pembrolizumab, for people with advanced stomach or pancreatic cancer that has spread and caused fluid buildup in the abdomen (malignant ascites). The study has two pa…

This study tests two drugs, avutometinib and defactinib, in people with a specific type of advanced stomach cancer called diffuse gastric cancer. The goal is to see if the combination can slow tumor growth or shrink tumors. About 27 adults who have already tried at least one stan…

This early-phase trial tests a combination of two drugs, neratinib and fam-trastuzumab deruxtecan (Enhertu), in people with advanced stomach, esophageal, or other gastrointestinal cancers that have a specific marker called HER2. The study aims to find the safest dose and see if t…

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This early-stage study is testing a new treatment called CEA-targeted CAR-T cells for people with advanced solid tumors like lung, stomach, colon, rectal, esophageal, or pancreatic cancer that have not responded to standard therapies. The treatment uses a patient's own immune cel…

This early-phase trial tests a personalized vaccine made from a patient's own tumor cells or donor cells. The cells are modified and killed in the lab, then injected under the skin to train the immune system to attack the cancer. The study includes 50 adults with metastatic melan…

This study tests whether a combination of three drugs (RC48, sintilimab, and SOX) can shrink advanced stomach cancer enough to allow surgical removal. It includes 30 adults with a specific type of HER2-positive cancer who have not had prior treatment. The goal is to see how many …

This phase II study is testing whether a new drug called SI-B003, alone or combined with BL-B01D1 or a PD-1 antibody, can shrink tumors in people with advanced esophageal, gastric, or colorectal cancer. About 376 participants will receive the treatments intravenously every three …

This phase 2 trial tests whether adding a daily pill containing a specific gut bacterium (EXL01) to standard immunotherapy (nivolumab) and chemotherapy (FOLFOX) can shrink tumors better than the drugs alone in people with advanced gastric cancer. About 120 participants will be ra…

This study tests two AI platforms to personalize cancer treatment for people with solid tumors like gastrointestinal or breast cancer. First, a platform called QPOP analyzes a patient's tumor sample to find the best drug combination. Then, another AI called CURATE.AI adjusts the …

This early-phase study tests a new drug called BL-M17D1 in 20 people with advanced HER2-positive gastrointestinal cancers (like stomach, pancreas, or colon cancer) or other solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether the …

This early-stage trial tests the safety and effectiveness of a new drug called JR8603 in people with advanced solid tumors, including stomach and colorectal cancers, who have not responded to standard treatments. Participants receive JR8603 by IV infusion three times per month. T…

This study tests whether taking oral sorbitol, a common sugar alcohol, can enhance the effects of standard chemotherapy and an immunotherapy drug (tirellizumab) in people with locally advanced stomach cancer. Eighty participants will receive either sorbitol or a placebo alongside…

This early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…

This early-phase trial is testing a new drug called SON-DP in 96 adults with advanced solid tumors, specifically liver and gastric cancers. The main goals are to check the drug's safety, find the right dose, and see if it can control the disease. Participants receive SON-DP throu…

This study is testing a blood test that looks for tiny bits of cancer DNA (ctDNA) in people with esophageal, gastric, or pancreatic cancer. The goal is to see if it can find signs of cancer coming back or getting worse earlier than current methods. About 34 participants will give…

This study tests a new radioactive tracer called [18F]FPyQCP for PET scans to see if it can better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the tracer and have a PET/CT scan. The goal i…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This early-stage trial is testing a new radioactive tracer called 68Ga-FXX489 (NNS309) for PET/CT scans. The goal is to see if it can safely and accurately detect tumors and their spread in 30 adults with suspected cancer. Researchers will measure how the tracer moves through the…

This study explores whether a magnetic resonance spectroscopy (MRS) scan of the thigh can predict a patient's fitness for major cancer surgery, as an alternative to the standard cardiopulmonary exercise test (CPET). Researchers will compare fat levels in thigh muscles from the MR…

This study aims to see if certain chemicals (oncometabolites) in a person's breath and blood can spot early-stage gastro-esophageal cancer. Researchers will compare samples from 1,000 people, including those with cancer, those with Barrett's esophagus (a precancerous condition), …

This study tests a special dye and imaging system to help surgeons see colorectal, pancreatic, esophageal, and stomach cancers during surgery. About 66 adults scheduled for cancer surgery will receive the dye, and the imaging system will check if it lights up cancer tissue. The g…

This study tests a new PET imaging probe that targets a protein called CLDN18.2, found in some stomach, pancreatic, bile duct, and esophageal cancers. Researchers will scan 56 people (patients and healthy volunteers) to see if the scan can accurately detect tumors and guide treat…

This study tests a special fluorescent dye that attaches to cancer cells to help doctors see if lymph nodes contain cancer during surgery for early gastric cancer. About 47 people with early gastric cancer will have their removed lymph nodes examined with this probe. The goal is …

This study is testing a simple, less invasive way to detect early signs of Barrett's esophagus, esophageal cancer, and stomach cancer. Participants swallow a capsule attached to a string, which expands into a sponge in the stomach to collect cell samples. Researchers then look fo…

This study tests whether a dye called pafolacianine (CYTALUX™) can make cancer cells glow under near-infrared light during surgery. Fifteen adults with gastric, esophageal, or appendiceal cancer will receive the dye before standard surgery. Surgeons will use a special camera to l…

This program offers a simple breath test to 50,000 Aboriginal people in remote Taiwan to detect H. pylori, a bacteria linked to stomach cancer. Those who test positive receive treatment to wipe out the infection. The goal is to see if this approach lowers cancer rates in a high-r…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests whether a program of physical therapy, nutritional planning, and psychological support before and after surgery can help patients with locally advanced esophageal, gastroesophageal junction, or stomach cancer recover better. Sixty participants will follow the pro…

This study compares two types of nerve blocks—coeliac plexus block and splanchnic nerve block—to see which one reduces pain better in adults with upper abdominal cancer. Forty-four participants will receive one of the procedures and be monitored for pain, opioid use, and quality …

This study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This trial compares a new surgery called partial stomach-partitioning gastrojejunostomy (SPGJ) to the standard surgery for relieving stomach blockage in advanced gastric cancer. The goal is to see which surgery better helps patients eat normally, with fewer complications like del…

This study tests a personalized rehabilitation program for people recovering from surgery for esophageal or gastric cancer. Participants will receive a structured assessment of their physical, psychological, and social needs, followed by evidence-based support. The goal is to imp…

This study tests a software tool called myDIET that helps manage nutrition in people with stomach or esophageal junction cancer who are scheduled for surgery. Patients answer simple questions about eating, weight, and symptoms, and the tool gives tailored advice. The goal is to s…

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This study compares a new nerve block (EOIB) to a standard combination of blocks for pain after laparoscopic stomach removal. 100 adults undergoing this surgery will be randomly assigned to receive one of the two blocks. The goal is to see if the new block is as good at reducing …

This study tests a newer nerve block technique (external oblique intercostal block) against a standard one (erector spinae plane block) for pain after laparoscopic stomach removal. About 184 adults having this surgery will be randomly assigned to one of the two blocks. The main g…

This study tests whether a new device that combines a bite block, oxygen tube, and airway support can prevent dangerously low oxygen levels in severely obese patients during sedated endoscopy. About 410 adults with a BMI of 35 or higher will be randomly assigned to receive either…

This study compares two minimally invasive nerve block techniques to relieve severe upper abdominal cancer pain that hasn't responded to standard treatments. About 56 adults with stomach, pancreatic, or liver cancer will receive either a transdiscal or paravertebral approach. The…

This trial tests whether a smartphone-based program combining exercise, nutrition advice, and psychological support can reduce complications and improve recovery in 186 gastric cancer patients undergoing neoadjuvant therapy and surgery. Participants follow the program from before…

This study tests whether fecal microbiota transplantation (FMT) – taking donor gut bacteria in capsules – can prevent or reduce gastrointestinal symptoms like nausea, vomiting, and diarrhea caused by chemotherapy or targeted therapy. It involves 90 adults with advanced (Stage IV)…

This study tests a new device called the COMBO Endoscopy Oropharyngeal Airway in 580 obese patients undergoing sedated gastrointestinal endoscopy. The device combines oxygen delivery, breathing monitoring, and a bite block to prevent low oxygen levels. Researchers will compare it…

This study looks at the bacteria living in the mouth, stool, and tumors of Colombian adults with advanced cancers of the stomach, colon, breast, cervix, or head and neck who are starting immunotherapy as standard care. Researchers will compare these microbial profiles to those of…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study follows 400 people aged 6 and older who have a rare stomach cancer called GIST. Researchers will collect tumor tissue during surgery and study it in the lab to learn more about the disease. Participants are monitored every 6 to 12 months for up to 10 years before surge…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study investigates whether the unique bacteria found inside digestive system tumors can help predict how well a patient will respond to neoadjuvant therapy (chemotherapy before surgery). Researchers will analyze tumor samples from 90 adults with pancreatic, gastric, colorect…

This study tests whether giving heated chemotherapy directly into the abdomen (HIPEC) can increase a protein called PD-L1 on stomach cancer cells that have spread to the lining of the belly. Higher PD-L1 levels might make these cancers more responsive to immunotherapy drugs. The …

This study is building a registry of people with gastric cancer, a family history of it, or a specific gene mutation (CDH1). Participants fill out online questionnaires and provide saliva, blood, or tissue samples. The goal is to learn more about what causes stomach cancer and ho…

Cancer patients face a higher risk of blood clots during chemotherapy, but it's hard to know who is most at risk. This study will measure clotting-related biomarkers in the blood of 380 patients with ovarian, lung, stomach, or pancreatic cancer at four points during their treatme…

This study aims to develop a model that uses genetic information from tumor tissue to predict how well gastric cancer patients will respond to chemotherapy. Researchers will analyze RNA splicing patterns and apply machine learning to identify patients who are less likely to benef…

This study is building a large database of 15,000 patients with esophageal or gastric cancers in France. Researchers will look back at medical records to see how patients fared after surgery, focusing on how long they stayed cancer-free. The goal is to learn more about survival, …

This study is testing whether a quick, non-invasive test that measures heart rate and breathing patterns before thoracic surgery can help predict which patients are more likely to have complications after the operation. Researchers will enroll 130 adults undergoing major chest su…

This study collects blood, urine, and bone marrow samples from 620 people with solid cancers like lung, colorectal, and pancreatic cancer. Researchers will look for tumor cells and DNA in these samples to understand how cancer spreads and why it sometimes comes back after surgery…

This study is investigating whether exposure to microplastics is linked to the development of stomach cancer and its early stages. Researchers will ask 450 people with different stomach conditions to fill out a detailed questionnaire about their possible exposure to microplastics…

This study is testing whether a personalized blood test that looks for tumor DNA can detect stomach cancer recurrence earlier than standard imaging. About 110 patients who had chemotherapy and surgery for stage II-III stomach cancer will give blood samples over time. The goal is …

This study looks at whether using a dye called indocyanine green (ICG) during surgery for advanced stomach cancer helps surgeons see cancer more clearly and change their approach. About 360 adults with stomach cancer will take part. The goal is to see if the dye improves how surg…

This study is developing an AI tool to predict the risk of serious bleeding after stomach cancer surgery. Researchers will collect data from 7,000 adult patients who had their stomach removed due to cancer. The goal is to help doctors decide earlier if a second surgery is needed,…

This study aims to understand why many cancer patients lose muscle and fat (cachexia), a condition that worsens their health. Researchers will use advanced techniques to analyze samples from 1000 adults with certain cancers. The goal is to find early warning signs and new targets…

This study looks at whether a blood test that detects tumor DNA (ctDNA) can help doctors monitor how well treatment is working in people with stomach cancer. About 600 participants will provide blood samples before and during treatment to see if changes in ctDNA levels predict re…

This study compares two types of staplers (linear vs circular) used to reconnect the esophagus to the small intestine after stomach removal surgery for gastric cancer. Researchers want to see which stapler leads to fewer complications and shorter surgery time. About 100 adults wi…

This study translates and validates a Korean quality-of-life questionnaire (KOQUSS-40) for Spanish-speaking patients who had stomach cancer surgery. Researchers will enroll 505 adults who are at least one month past surgery and cancer-free. The goal is to create a reliable tool t…

This study looks at how common Helicobacter pylori infection is in people newly diagnosed with stomach cancer in Martinique. Researchers will collect tumor samples, healthy tissue, and blood to build a biobank. The goal is to understand why stomach cancer is more common in the We…

This observational study will follow 1,000 adults in Algeria who have been diagnosed with gastric cancer. Researchers will collect information on patient demographics, risk factors, symptoms, how the cancer is diagnosed, and what treatments are used. The goal is to better underst…

This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to cancer treatment can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online …

This study looks at tissue samples from 30 adults with stomach or esophageal cancer that spread to the brain. Researchers compare the genetic markers of the original tumor and the brain tumor to see if they differ. The goal is to better understand how these cancers change when th…

This study collects tissue, blood, urine, and stool samples from 5000 people undergoing colonoscopy or endoscopy, including those with cancer, polyps, or inflammatory bowel disease, as well as healthy volunteers. The goal is to find new biomarkers that could improve early detecti…

This study looks at how well patients understand the information they get before major abdominal cancer surgery and whether that affects regret afterward. Researchers will survey 90 adults before surgery, then one month and three months after. The goal is to improve how doctors c…

This study uses a 20-25 minute survey to find out which features of diagnostic tests for gastro-esophageal cancer matter most to patients and the general public. Researchers aim to understand preferences and regional differences to improve screening decisions. About 2,200 adults …

This study is testing whether a monthly blood test can predict dangerous blood clots in people with certain cancers (lung, pancreatic, stomach, or brain). Cancer patients are at high risk for clots, which can be deadly. Researchers will follow 200 participants for 12 months, taki…

This study is looking at whether the bacteria in your gut can predict how well a combination of immunotherapy and chemotherapy works for advanced stomach cancer. Researchers will track 300 patients and check their gut bacteria at several points during treatment. The goal is to fi…

This study looks at people with a specific genetic change in the CTNNA1 gene, which may increase the risk of stomach and breast cancers. Researchers will collect family health histories from 100 participants to better understand these risks. The goal is to improve cancer screenin…

This study is looking for markers in the blood that might show early signs of stomach cancer or conditions that can lead to it. Researchers will follow about 192 adults who are already getting stomach function tests. The goal is to see if changes in these markers over time can he…

This study is building a registry of 3,200 people with early changes in the stomach lining that can lead to gastric cancer. Researchers will collect information on lifestyle, diet, and other risk factors through questionnaires. The goal is to better understand why some people dev…

This study looks back at 1,200 people who had a breathing tube placed during surgery to find out how often voice box injury happens and what makes it more likely. Researchers will check medical records and call patients to see if they had hoarseness or other throat problems after…

This study is observing 50 adults with advanced cancers (lung, breast, colorectal, gastric, or liver) who are starting immunotherapy. Researchers want to see if changes in ctDNA (bits of tumor DNA in the blood) can predict early whether the treatment is working. They will also ch…

This study looks at how a specific gene change (called hMLH1 hypermethylation) affects stomach cancer. Researchers will study 245 patients who had stomach cancer surgery to find links between lifestyle, genetics, and how the cancer behaves. The goal is to better understand why so…

This study looks at using endoscopic vacuum therapy to treat leaks that can happen after stomach cancer surgery. Researchers will track 100 patients to see if this approach lowers death rates, reduces complications, and improves patient satisfaction. The goal is to find a better …

This study follows 600 people at higher risk for stomach cancer to track precancerous changes in the stomach lining. Researchers collect tissue, blood, and saliva samples during routine endoscopies. The goal is to understand why some people's stomach changes progress to cancer wh…

This study follows 200 people with cancers of the esophagus, stomach, pancreas, colon, or rectum who are scheduled for surgery, along with some healthy controls. Researchers will track weight, muscle mass, physical activity, quality of life, and immune markers over a year to bett…

This study tests a new method to help choose cancer drugs for people with hard-to-treat solid tumors. Doctors take a small piece of the tumor, grow it in the lab, and test many drugs on it to see which works best. Then they give that drug to the patient. The goal is to see if thi…

This study is testing a new blood test to find tiny traces of stomach cancer that might be left behind after surgery. The goal is to catch a recurrence earlier than standard scans. Researchers will collect blood samples from 500 people who had their stomach cancer removed and fol…

This study looks at 100 adults in Guadeloupe who have just been diagnosed with stomach cancer. Researchers want to find out how many of them also have an H. pylori infection, a bacteria linked to stomach cancer. By testing tissue and blood samples, they hope to learn more about t…

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

This study is testing whether measuring ctDNA (bits of tumor DNA) in blood or stool can help doctors manage patients with cancers of the digestive tract, including pancreas, colon, and bile duct cancers. Researchers will track survival and see how these markers relate to outcomes…